Delving into the Latest Updates on Avva Pharmaceuticals Ltd. with Synapse

An Open-label, Randomized, Cross-over, Comparative Study of ALCOFILTRUM Dietary Food Supplement for Alleviating Alcohol Hangover Symptoms in Healthy Volunteers

The aim of this open-label, randomized, crossover, comparative pilot study is to assess efficacy and safety of the dietary food supplement ALCOFILTRUM in healthy volunteers who consume alcohol. Specifically the study will evaluate:
Efficacy of the intervention to alleviate hangover symptoms in participants who consumed alcohol,
Safety of intervention in participants who consuming alcohol.
Participants will take four tablets of ALCOFILTRUM dietary food supplement 30 minutes before alcohol ingestion, while the control group will intake only alcohol drink.

开始日期2022-03-03

申办/合作机构

Avva Pharmaceuticals Ltd.

100 项与 Avva Pharmaceuticals Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Avva Pharmaceuticals Ltd. 相关的专利（医药）

登录后查看更多信息

2

项与 Avva Pharmaceuticals Ltd. 相关的文献（医药）

Metabolites

Fecal Microbiota and Associated Volatile Organic Compounds Distinguishing No-Adenoma from High-Risk Colon Adenoma Adults

Article

作者: Nikolaou, Elpiniki ; Costeas, Paul ; Chi, Jianxiang ; Shammas, Christos ; Frangou, Elisavet ; Brown, Cameron ; Yiannakou, Danae ; Potamitis, George ; Katsaounou, Kyriaki ; Agapiou, Agapios ; Tsiaoussis, George ; Apidianakis, Yiorgos ; Antoniades, Athos ; Aristodimou, Aristos ; Vogazianos, Paris

Microbiota and the metabolites they produce within the large intestine interact with the host epithelia under the influence of a range of host-derived metabolic, immune, and homeostatic factors. This complex host–microbe interaction affects intestinal tumorigenesis, but established microbial or metabolite profiles predicting colorectal cancer (CRC) risk are missing. Here, we aimed to identify fecal bacteria, volatile organic compounds (VOC), and their associations that distinguish healthy (non-adenoma, NA) from CRC prone (high-risk adenoma, HRA) individuals. Analyzing fecal samples obtained from 117 participants ≥15 days past routine colonoscopy, we highlight the higher abundance of Proteobacteria and Parabacteroides distasonis, and the lower abundance of Lachnospiraceae species, Roseburia faecis, Blautia luti, Fusicatenibacter saccharivorans, Eubacterium rectale, and Phascolarctobacterium faecium in the samples of HRA individuals. Volatolomic analysis of samples from 28 participants revealed a higher concentration of five compounds in the feces of HRA individuals, isobutyric acid, methyl butyrate, methyl propionate, 2-hexanone, and 2-pentanone. We used binomial logistic regression modeling, revealing 68 and 96 fecal bacteria-VOC associations at the family and genus level, respectively, that distinguish NA from HRA endpoints. For example, isobutyric acid associations with Lachnospiraceae incertae sedis and Bacteroides genera exhibit positive and negative regression lines for NA and HRA endpoints, respectively. However, the same chemical associates with Coprococcus and Colinsella genera exhibit the reverse regression line trends. Thus, fecal microbiota and VOC profiles and their associations in NA versus HRA individuals indicate the significance of multiple levels of analysis towards the identification of testable CRC risk biomarkers.

Metabolites

Colon Cancer: From Epidemiology to Prevention

Review

作者: Teloni, Savvas ; Shiammas, Christos ; Zaravinos, Apostolos ; Brown, Cameron ; Katsaounou, Kyriaki ; Apidianakis, Yiorgos ; Potamitis, George ; Stavrou, Marios ; Andreou, Chrysafis ; Tsiaoussis, Georgios ; Vogazianos, Paris ; Fragkou, Elisavet ; Antoniades, Athos ; Hatzis, Pantelis ; Agapiou, Agapios ; Nicolaou, Elpiniki

Colorectal cancer (CRC) is one of the most prevalent cancers affecting humans, with a complex genetic and environmental aetiology. Unlike cancers with known environmental, heritable, or sex-linked causes, sporadic CRC is hard to foresee and has no molecular biomarkers of risk in clinical use. One in twenty CRC cases presents with an established heritable component. The remaining cases are sporadic and associated with partially obscure genetic, epigenetic, regenerative, microbiological, dietary, and lifestyle factors. To tackle this complexity, we should improve the practice of colonoscopy, which is recommended uniformly beyond a certain age, to include an assessment of biomarkers indicative of individual CRC risk. Ideally, such biomarkers will be causal to the disease and potentially modifiable upon dietary or therapeutic interventions. Multi-omics analysis, including transcriptional, epigenetic as well as metagenomic, and metabolomic profiles, are urgently required to provide data for risk analyses. The aim of this article is to provide a perspective on the multifactorial derailment of homeostasis leading to the initiation of CRC, which may be explored via multi-omics and Gut-on-Chip analysis to identify much-needed predictive biomarkers.

100 项与 Avva Pharmaceuticals Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Avva Pharmaceuticals Ltd. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月18日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

4

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Acetylcholinesterase Inhibitor(AVVA) ( AChE )	阿尔茨海默症更多	临床前
Anti-IL-26 Antibody(AVVA) ( IL26 )	银屑病更多	临床前
GLP1R Agonist(AVVA) ( GLP-1R )	阿尔茨海默症更多	临床前
Age DRP(AVVA)	糖尿病性视网膜病变更多	临床前